www.fdanews.com/articles/156953-vertex-receives-australian-approval-for-kalydeco
Vertex Receives Australian Approval for Kalydeco
July 10, 2013
Australia’s Therapeutic Goods Administration has approved Vertex’s Kalydeco, a drug that treats the underlying cause of cystic fibrosis in patients with the G551D mutation.
Businesswire
Businesswire